Ultrasound Guided Diuretic Therapy in Type 1 Cardiorenal Syndrome

Ultrasound Guided Diuretic Therapy in Type 1 Cardiorenal Syndrome

A double-blind, randomized, controlled trial was conducted with the main objective of evaluating if patients with clinical assessment and VExUS reach decongestion faster within a maximum period of 7 days during the hospital stay. Likewise, the study will describe those patients who experience a decrease in serum creatinine (CrS), NT-proBNP at discharge, greater diuretic adjustment, rate of intrahospital readmission, and 30-day mortality.

Inclusion Criteria:

• 18 years old or older
• Type 1 cardiorenal syndrome in emergency room at Instituto Nacional de Cardiologia Ignacio Chávez

Exclusion Criteria:

• Patients who denied to participate
• Liver disease (cirrohsis)
• Complex congenital heart disease
• Kidney transplant
• Heart transplant
• Severe valvular disease
• Chronic kidney disease KDIGO G5 and G5d
• INTERMACS Score 2